Jose Luis Pelaez Inc/DigitalVision via Getty Images Paymentus (NYSE:PAY) is a company providing bill payment technology and solutions for over 2,200 billers in North America. PAY generates most of its revenues from transaction fees, and therefore benefits from the fact that it focuses on non-discretionary target verticals, such as utilities, financial services, or healthcare. Despite…
JulPo Overview My recommendation for PAR Technology (NYSE:PAR) is a buy rating, as I expect growth to continue into the near term. Especially with the addition of Stuzo and potentially TASK, I believe the growth outlook has gotten a lot more positive than when I last looked at the company. Note that I previously rated…
Just_Super/iStock via Getty Images Medtronic PLC (NYSE:MDT) is a global developer and manufacturer of medical devices for chronic diseases. Founded in 1949, Medtronic is now a $111 billion (by market cap) healthcare behemoth that employs 95,000 people. The company reports results across four segments: Cardiovascular, 37% of FY 2023 revenue; Neuroscience, 29%; Medical Surgical, 27%;…
AntaresNS/iStock via Getty Images Introduction In the summer of 2022, I argued Glacier Bancorp, Inc. (NYSE:GBCI) was a well-run Montana focused bank, but I wasn’t willing to pay 3 times the tangible book value, or TBV, for the bank. Fast-forward to now, just over eighteen months later, and the bank’s share price has indeed come…
PATRICK T. FALLON/AFP via Getty Images Recap In June last year, we wrote an article suggesting that Charter’s (NASDAQ:CHTR) fixed-line broadband net adds will pick up thanks to slowing Fixed Wireless Access (“FWA”) growth, existing network upgrades, and accelerating rural build-out. Shares traded at $336, 60% down from their all-time high. The stock eventually climbed…
Diego Thomazini Even though the earnings reports from Amazon (AMZN), Meta (META) and Apple (AAPL) aren’t in the data because LSEG cuts off the earnings and market data as of Thursday night’s market close, the upside surprise for Q4 ’23 S&P 500 EPS closed the week at +6.4%, versus the +7.2% from Q3 ’23. That…
Wirestock Since I last wrote an earnings preview on pharmaceuticals company GSK plc (NYSE:GSK) last October, its price is up by 11.8%, which was to be expected on good results and the settlement of its heartburn medication, Zantac, related cases in California. With full-year 2023 results expected at the end of the month, a continued…
Vertigo3d I have a small stake and high hopes in REGENXBIO (RGNX), however RGNX stock has consistently failed to perform. From my last article in May, the stock is down 26%. The latest fall came after they announced “positive” interim data two days ago from their “Phase II AAVIATE® trial of ABBV-RGX-314 for the treatment…
Gary Yeowell/DigitalVision via Getty Images Investment Rundown The rail industry can be quite difficult to invest in. I often think it’s a very good reflection of how an economy does, if there is high activity the economy is most likely doing good, and vice versa. With Trinity Industries, Inc. (NYSE:TRN) you are getting a slightly…
La_Corivo Introduction Pan American Silver (NYSE:PAAS) is one of my favorite silver miners. Since Yamana’s acquisition, the company has added quality assets, considerably expanding its reserves and resource base. PAAS assets are in countries with relatively low political risk in the Western Hemisphere. Besides that, the revenue per country does not exceed 25%. 3Q23 production…
Andrii Yalanskyi/iStock via Getty Images Thesis General American Investors (GAM) is an equity CEF. We have covered this name before here, when we assigned it a ‘Hold’ rating based on its intrinsic characteristics. We are revisiting this name based on a very interesting development in the market this past year: most equity CEFs tracking the…
SBWorldphotography/iStock via Getty Images The more dovish narrative that has overtaken the markets since December, resulting in the S&P 500 sitting close to a fresh all-time high, means excessive value exposure might hurt returns in 2024. Obviously, this is not an opportune moment for investment vehicles like the Invesco S&P SmallCap 600 Pure Value ETF…
pixelfit At a Glance BridgeBio Pharma’s (NASDAQ:BBIO) path has notably shifted. Since my last review, their FDA filing for acoramidis and advancements in cancer treatment, especially for KRAS mutations, are notable. However, financial hurdles are still evident, with a growing net loss and rising shares hinting at possible dilution of shareholder value. Their current ratio…
Spencer Platt The Health Care sector was one to generally avoid in 2023. Unless you were significantly overweight (no pun intended) in shares of Eli Lilly (LLY) and Novo Nordisk (NVO), it’s probable that you underperformed the S&P 500 given the Health Care Select Sector SPDR ETF’s (XLV) weak returns. Has the tide turned in…
PixelsEffect A logical pick cut in half There haven’t been many, if any drawdowns of this caliber to grab Pfizer (NYSE:PFE) -50% off highs. The company is down for good reason, investment in the Covid Vaccine solutions has left the company behind from an R&D perspective. While products related to MRNA Covid vaccines continue to…
Love Employee/iStock via Getty Images Xeris Biopharma Holdings (NASDAQ:XERS) is up 88% (YoY) and the stock price is trading just 23.5% shy of the 52-week high of $3.07. It has been four years since the U.S. FDA approved Gvoke, the prefilled (ready-to-use) glucagon drug for the treatment of hypoglycemia in diabetes patients (from 2 years…
adventtr Investment action I recommended a buy rating for Infineon (OTCQX:IFNNY) when I wrote about it the last time, as I expected growth to normalize as the business continues to clear its backlog. Doing so, the market should eventually re-value its multiple to its peers’ level. The stock took a big dive before recovering, and…
The Bureau of Economic Analysis reported that GDP increased at a 4.9% annualized rate in Q3, slightly below the previously reported 5.2% pace. The latest report from the United States Labor Department reveals a marginal increase in weekly jobless claims, with the number rising by 2,000 to 205,000 for the week ending December 16. While…
Phynart Studio/E+ via Getty Images Investment Thesis In recent months, Quipt Home Medical (NASDAQ:QIPT) has continued its impressive journey of growth and strategic expansion. The company has remained focused on its mission of becoming a leading provider in the home medical equipment sector, leveraging both organic and inorganic growth strategies. This commitment is evident in…
ANNVIPS Investment Thesis D.R. Horton (NYSE:DHI) stands out as a solid investment in the US homebuilding industry. They have consistently demonstrated an ability to navigate shifting housing market trends, a crucial factor in an industry often subject to economic fluctuations. Despite rising interest rates and inflation, DHI’s sales are up 8% this year. The current…
reklamlar/iStock via Getty Images Sprinklr (NYSE:CXM) is a company that develops SaaS for customer experience management across various channels, including social media. In the last four years, Sprinklr has been consecutively named in Gartner’s Magic Quadrant for Content Marketing Platforms, highlighting its capabilities in optimizing content management and maximizing client engagement. Unsurprisingly, CXM reported robust…
tianyu wu In this comprehensive analysis, we explore the performance and strategic direction of Eaton Corporation (NYSE:ETN), one of the leading names in power management. Beyond the surface of quarterly earnings, we delve into the company’s business strategy, its response to market trends, and its management of various challenges. Eaton’s ability to deliver impressive financial…
LeoWolfert/iStock via Getty Images I assessed N-able, Inc. (NYSE:NABL) a year ago and suggested a hold rating, considering its declining stock trend post-spinoff from SolarWinds Corporation. Despite robust financial performance, uncertainties in the IT industry and limited financial history prompted a cautious approach. However, its recent Q3 2023 report reveals a 15% YoY revenue surge…
SweetBunFactory In the recent Fiscal Q4 earnings report, Applied Materials, Inc. (NASDAQ:AMAT) has exhibited a strong financial performance, surpassing estimates and demonstrating robust growth across multiple segments. Despite an ongoing U.S. criminal investigation related to potential evasion of export restrictions, the company maintains a positive outlook. While the investigation has indeed cast a shadow over…
Suriyapong Thongsawang Introduction Tsakos Energy (NYSE:TNP) is one of the leading companies in the crude and product tanker industry. The company is run by its founders, who own a large portion of the shares through Tsakos Foundation and Tsakos Energy management. The company has a diverse fleet of crude and product tankers. Fleet average age…
Michael Vi Palantir (NYSE:PLTR) reported both top-line and bottom-line beats in Q3 FY23, along with raised full-year guidance. I am encouraged by their profitability growth, achieving a 29.3% adjusted operating margin. I anticipate further margin expansion in the coming years. However, I don’t believe their operating margin can reach the levels of most typical software…
FatCamera Investment action I recommended a buy rating for Molina Healthcare, Inc. (NYSE:MOH) when I wrote about it the last time, driven by my belief that the market was undervaluing its evident potential for growth. After a thorough review of MOH’s third quarter results, my conviction has only strengthened. The company has showcased robust growth,…
Robert Way Summary Following my coverage of L’Oréal (OTCPK:LRLCF), I recommended a buy rating due to my expectation that LRLCF’s growth and margins would recover towards normalcy. This post is to provide an update on my thoughts on the business and stock. I reiterate my buy rating for LRLCF due to its strong current quarter…
SweetBunFactory Investment Action In the second quarter of 2023, GlobalFoundries Inc (NASDAQ:GFS) demonstrated commendable financial performance. This achievement was not merely a result of favorable market conditions but also a testament to the company’s strategic foresight and adaptability. Their robust demand in sectors like automotive, industrial IoT, and aerospace and defense underscore their pivotal role…
Sundry Photography The fast-evolving world of technology is working in favor of online education firms like Coursera, Inc. (NYSE:COUR). This is because there is a growing demand for learning new skills or improving existing ones, which is driving the growth of Coursera’s online education services. Although the company’s stock value dropped by 65% since its…
JHVEPhoto Dear readers/followers, Assa Abloy (OTCPK:ASAZF) is a company that I’ve been following for a long time, and my investment in the company is old. I’ve remained positive for most of the time based on the company’s timeless fundamentals and growth prospects. This is, therefore, an update on the business since the last piece which…
BalkansCat/iStock Editorial via Getty Images Thesis Toronto-Dominion Bank (NYSE:TD) is the second-largest bank in Canada. Its balance sheet is neat and clean, with adequate liquidity to weather potential economic downturns. Typical for Canadian banks, TD has paid dividends even during crises such as GFC 2008. Its business is well diversified geographically between the US and…
chiewr Thesis Hercules Capital (NYSE:HTGC) is an exciting income investment offering a 10% yield, a robust balance sheet, and strong growth prospects. The company is uniquely positioned in the venture capital industry. It has two advantages: it is internally managed and debt-focused. The former is a rare bird in the VC business. Being a managed…
kyonntra/E+ via Getty Images Introduction ORIC Pharmaceuticals (NASDAQ:ORIC), a clinical-stage biopharmaceutical company, is dedicated to addressing drug resistance in cancer. Their clinical portfolio includes ORIC-114 for EGFR and HER2 mutations, ORIC-533 targeting CD73 to enhance chemotherapy and immunotherapy, and ORIC-944 for advanced prostate cancer. They are also engaged in early-stage projects to combat various other…
joji/E+ via Getty Images Investment Action Based on my outlook and analysis of The Vita Coco Co. (NASDAQ:COCO), I recommend a buy rating. I expect COCO to continue tracking against its growth targets, albeit with a slowdown in FY24 due to the private label transition. The strong growth and EBITDA margin expansion should support its…
JHVEPhoto Investment Thesis Accenture (NYSE:ACN) stands as one of the leading companies in the digital consulting sector, which has played a pivotal role in driving the digitalization of the economy – a trend that’s expected to persist in the coming years. As illustrated in the chart, the company’s stock price has aptly reflected this, consistently…
wildpixel Introduction Karuna Therapeutics (NASDAQ:KRTX) develops innovative treatments for psychiatric and neurological disorders. Their investigational drug, KarXT, targets schizophrenia and Alzheimer’s-related psychosis with a unique mechanism, differing from dopaminergic or serotonergic pathways, offering a potential new treatment option. In my previous analysis of Karuna Therapeutics, I highlighted the potential of their antipsychotic drug, KarXT, to…
MicroStockHub Executive Summary Cincinnati Financial (NASDAQ:CINF) recently released its quarterly results, showing an impressive turnaround in net income from a $818 million loss in the previous year to a profit of $534 million. Year-to-date post-tax profit also rose significantly by $1.8 billion to reach $759 million, mainly due to unrealized equity gains, in contrast to…
Receive free Bank stress tests updates We’ll send you a myFT Daily Digest email rounding up the latest Bank stress tests news every morning. Only three of Europe’s 70 biggest banks would be forced to raise capital in a doomsday scenario, the EU’s top banking regulator said on Friday, as it praised the “robust” nature…